Antiaging Quantum Living Inc (AAQL)

[Ro the Bull]

Not sure on the severity of the enzymes that were elevated. Would have to revisit the articles that discussed it to determine how significant an adverse event it was deemed to be. was serious enough to get the FDA's attention though.

A little suspicious that the CEO change happened not long before the trial was put on hold. I wonder if he was pushing something against popular demand within the company's research division...

The new CEO was touting that they have their own 3 part combo to rival the Pharmasset/Gilead product... Here's a good release discussing their pipeline.

http://ir.achillion.com/releasedetail.cfm?releaseid=831214

This summarizes the response timeframes anticipated late last year. Hopefully there will be resolution shortly. Though it does sound like there is a discrepancy of opinion between what the company things should remove the hold and what the FDA thinks...

http://www.biotechnologyevents.com/node/7251


They also picked up Kevin Kucharski, who ran Pharmasset's clinical operations. That tends to mean he'll eventually reassemble the substantive portion of the team that did the trial management for Pharmasset, and prior...

http://www.thestreet.com/story/11923750/2/achillion-appoints-dr-david-apelian-as-chief-medical-officer-and-expands-clinical-operations-team.html

Disclosure: I bought in last summer, and tripled down after the steep decline and a couple of dead cat bounces. I plan on being long until either a deal is announced or they get going on their own, which will be a much longer, slower ride.